• Facets (new session)
• Description
• Metadata
• Settings
  • Rule: ActivityStreamsMapasEquivalentb3sb3sifpdbprdf-labelfacetshttp://dbpedia.org/resource/inference/rules/dbpedia#http://dbpedia.org/resource/inference/rules/opencyc#http://dbpedia.org/resource/inference/rules/umbel#http://dbpedia.org/resource/inference/rules/yago#http://dbpedia.org/schema/property_rules#http://www.ontologyportal.org/inference/rules/SUMO#http://www.ontologyportal.org/inference/rules/WordNet#http://www.w3.org/2002/07/owl#ldpoplwebskos-transurn:det:rdf:labelvirtrdf-labelvirtrdf-urlNone
    
  • Inverse Functional Properties: Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects
  • "Same As": Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects (recommended) Apply to subjects, objects and predicates (not recommended on big datasets) Apply to predicates only (special use cases only)

About: dbr:Erlotinib     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : umbel-rc:DrugProduct, within Data Space : dbpedia.org associated with source document(s)

Type: Thingdul:ChemicalObjectchemical substanceDrugyago:WikicatAminesyago:Abstraction100002137yago:Acetylene114600742yago:AliphaticCompound114601294yago:Amine114739004yago:Base114618253yago:Chemical114806838yago:Compound114818238yago:Element114840755yago:Material114580897yago:Matter100020827yago:MethaneSeries114951377yago:OrganicCompound114727670yago:Part113809207yago:PhysicalEntity100001930yago:Pyrimidine114999913yago:Quintessence114847103yago:Relation100031921drugyago:Substance100019613yago:WikicatAlkynesyago:WikicatEthersyago:WikicatPhenolEthersyago:WikicatPyrimidinesumbel-rc:DrugProduct New Facet based on Instances of this Class

Erlotinib, sold under the brand name Tarceva among others, is a medication used to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. Specifically it is used for NSCLC with mutations in the epidermal growth factor receptor (EGFR) — either an exon 19 deletion (del19) or exon 21 (L858R) substitution mutation — which has spread to other parts of the body. It is taken by mouth. Erlotinib was approved for medical use in the United States in 2004. It is on the World Health Organization's List of Essential Medicines.